Across tumor types, 1-year NGS uptake rose substantially from 2018 to 2022, reaching 74.5% in aNSCLC and 78.1% in mCRC, but ...
While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...
The partnership pairs Pillar's portfolio of oncoReveal (R) kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduce screening friction, improve turnaround time, ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Biomarker testing has the potential to streamline diagnosis, treatment planning, and anticipation of treatment risks, if done right.
NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor The Prostate Cancer Precision Medicine Multi ...
To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...
Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results